QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brown, J. Articles by Freeman, B. B Search for Related Content PubMed PubMed Citation Articles by Brown, J. Articles by Freeman, B. B, III

INFECTIOUS DISEASES

Combining Quinupristin/Dalfopristin with Other Agents for Resistant Infections

Infectious Disease Clinical Pharmacist Specialist, Department of Infectious Disease and Pharmacy, Dartmouth-Hitchcock Medical Center, Lebanon, NH

Burgess B Freeman, III, PharmD

at time of writing, Pharmacy Resident, Department of Pharmacy, Ohio State University Medical Center, Columbus, OH; now, Post-Doctoral Fellow, Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN

Reprints: Jack Brown PharmD, Department of Pharmacy, Dartmouth-Hitchcock Medical Center, One Medical Center Dr., Lebanon, NH 03756-0001, fax 603/650-4454, Jack.E.Brown{at}Hitchcock.org

OBJECTIVE: To review the resistance mechanisms of Enterococcus and Staphylococcus spp. and summarize quinupristin/dalfopristin's (QD's) effects on these resistant organisms when combined with other antibiotics via review of the literature and unpublished data.

DATA SOURCES: Data were identified by a PubMed search (1996–May 2003) using the search terms quinupristin/dalfopristin, synergy, in vitro, in vivo, vancomycin-resistant Enterococcus faecium (VREF), methicillin-resistant Staphylococcus aureus (MRSA), and individual antibiotic names. Bibliographies of the resultant PubMed searches were reviewed and included if applicable.

STUDY SELECTION AND DATA EXTRACTION: All studies reviewed were analyzed; specific drug data were included only if clinically pertinent. In vitro data from studies with adequate design were discussed, whereas all case reports and clinical trials were utilized.

DATA SYNTHESIS: In the treatment of VREF, available information seems conflicting, although some clear differences have become apparent. QD–ampicillin and QD–doxycycline combinations have demonstrated beneficial activity, usually displaying synergistic or additive effects even in macrolide-, lincosamine-, and streptogramin-resistant (MLS_B) isolates. Vancomycin and chloramphenicol have shown some efficacy, but antagonistic or null results also have been observed. Regarding MRSA, results from many studies of QD combinations have been ambiguous. More common combinations displayed synergy or additive effects against MRSA, but only QD–rifampin showed consistent beneficial activity against MRSA and MLS_B isolates. Most other combinations displayed antagonism when tested in vitro.

CONCLUSIONS: Data supporting the use of various QD–antibiotic combinations against VREF and MRSA are increasing, but further in vitro and in vivo data are needed to confirm the findings.

Key Words: dalfopristin, methicillin-resistant Staphylococcus aureus, quinupristin, synergy, vancomycin-resistant Enterococcus faecium

Published Online, February 27, 2004. www.theannals.com, DOI 10.1345/aph.1D323

This article has been cited by other articles:

				M. Scheetz, P. Reddy, M. Postelnick, and J. Flaherty In vivo synergy of daptomycin plus a penicillin agent for MRSA? J. Antimicrob. Chemother., March 1, 2005; 55(3): 398 - 399. [Full Text] [PDF]